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Abstract
Nonsteroidal anti-inflammatory drugs have been shown to reduce the incidence of gastroin-
testinal cancers, but the propensity of these drugs to cause ulcers and bleeding limits their
use. H2S has been shown to be a powerful cytoprotective and anti-inflammatory substance
in the digestive system. This study explored the possibility that a H2S-releasing nonsteroidal
anti-inflammatory drug (ATB-346) would be effective in a murine model of hereditary intesti-
nal cancer (APCMin+ mouse) and investigated potential mechanisms of action via transcrip-
tomics analysis. Daily treatment with ATB-346 was significantly more effective at preventing
intestinal polyp formation than naproxen. Significant beneficial effects were seen with a
treatment period of only 3–7 days, and reversal of existing polyps was observed in the
colon. ATB-346, but not naproxen, significantly decreased expression of intestinal cancer-
associated signaling molecules (cMyc, β-catenin). Transcriptomic analysis identified 20
genes that were up-regulated in APCMin+ mice, 18 of which were reduced to wild-type levels
by one week of treatment with ATB-346. ATB-346 is a novel, gastrointestinal-sparing anti-
inflammatory drug that potently and rapidly prevents and reverses the development of pre-
cancerous lesions in a mouse model of hereditary intestinal tumorigenesis. These effects
may be related to the combined effects of suppression of cyclooxygenase and release of
H2S, and correction of most of the APC
Min+-associated alterations in the transcriptome.
ATB-346 may represent a promising agent for chemoprevention of tumorigenesis in the GI
tract and elsewhere.
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Introduction
Although significant progress has been made in the detection, diagnosis and identification of
specific molecular mechanisms of colorectal cancer, there is currently no cure for this disease
[1]. The predominant form of hereditary cancer in the small and large intestine is known as
Familial Associated Polyposis (FAP), which is mainly linked to defects in the Adenomatous
Polyposis Coli (APC) gene. Moreover, seventy percent of sporadic colorectal cancers are due to
bi-allelic inactivation of the APC gene. APC is a protein involved in the Wnt/β-catenin signal-
ing pathway. Mutations in this signaling pathway are the only known genetic alterations pres-
ent in early premalignant lesions in the intestine, such as aberrant crypt foci and small
adenomas or polyps. Constitutive activation of the Wnt signaling pathway caused by mutations
in components of the pathway has been suggested to be responsible for the initiation of colo-
rectal cancer [2].
The experimental models used to study colorectal cancer largely involve use of animals with
mutations in Wnt/β-catenin signaling pathway or by chemically stimulating alterations in
these pathways to initiate tumorigenesis in the intestine. One of the most commonly used mod-
els is the heterozygous ApcMin/+ mouse [3]. This mouse is similar to human FAP in that it car-
ries a mutation in the APC gene, predisposing them to develop multiple colonic and small
intestinal polyps and adenomas.
There are extensive data suggesting that regular use of nonsteroidal anti-inflammatory
drugs (NSAIDs) can markedly reduce the incidence of intestinal cancer [4,5]. Moreover,
NSAIDs have been shown to have significant chemopreventative effects in numerous animal
models of intestinal cancer [6,7]. The mechanism underlying the chemopreventative actions of
NSAIDs are not clear, though suppression of prostaglandin E2 synthesis, particularly via inhi-
bition of cyclooxygenase (COX)-2 activity, has been suggested to be important [8]. The major
limitation to the widespread use of NSAIDs to reduce cancer risk in humans is the significant
gastrointestinal (GI) adverse effects of these drugs. NSAIDs induce ulceration and bleeding
throughout the GI tract, and such damage is more common in the elderly and in patients tak-
ing other anti-coagulants and with co-morbidities such as rheumatoid arthritis, hypertension
and obesity [9,10]. Since the introduction of selective COX-2 inhibitors at the start of the 21st
century, physicians have become more aware of the significant risks of serious cardiovascular
adverse effects of NSAIDs that further limit the use of this class of drugs for chemoprevention
of cancer [11].
Hydrogen sulfide (H2S) is an endogenous signaling molecule with a wide range of anti-
inflammatory, anti-oxidant and cytoprotective actions [12,13]. As well as directly scavenging
reactive oxygen species [14,15] and inhibiting myeloperoxidase activity [16], H2S has been
shown to production of several pro-inflammatory cytokines (by inhibiting nuclear factor
kappa-light-chain-enhancer of activated B cells (Nf-KB) activity) [17], and to activate the Nrf2
(nuclear factor {erythroid-derived 2}-like 2)-regulated antioxidant response elements [18], pos-
sibly via protein S-sulfhydration [19]. H2S also exerts potent protective and reparative effects
in the GI tract, some of which may be mediated, in part, through its anti-oxidant actions [20–
23]. These powerful effects of H2S have been exploited in the development of several novel
drugs [12]. For example, H2S-releasing derivatives of several NSAIDs have been developed
with a primary aim of producing anti-inflammatory drugs with greatly reduced GI toxicity
[12,20,24–26]. H2S-releasing NSAIDs have also been shown to exert significant beneficial
effects in various rodent tumorigenesis models [27–30]. For example, an H2S-releasing deriva-
tive of the NSAID naproxen (ATB-346) produced significantly greater chemopreventative
effects than equimolar doses of naproxen in the azoxymethane-induced tumorigenesis model
in rats, without causing the significant GI injury caused by naproxen [30]. The suppression of
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GI prostaglandin synthesis by ATB-346 was comparable to that produced by naproxen, sug-
gesting that effects other than suppression of COX activity accounted for the enhanced chemo-
preventative potency of this H2S-releasing drug [30].
In the present study, we have further evaluated the chemopreventative effects of ATB-346
versus naproxen, using the ApcMin/+ mouse model that closely mimics human FAP [3]. We
have also attempted to identify potential mechanisms of action, including through a transcrip-
tomics analysis of the effects of the two drugs.
Materials and Methods
Animals
Male C57BL/6 and ApcMin/+ mice were from Jackson Laboratories (Bar Harbor, MA, USA). All
mice were housed in the Central Animal Facility at McMaster University. The mice were fed
standard chow and water ad libitum, and were housed in a room with controlled temperature
(22 ± 1°C), humidity (65–70%) and light cycle (12 h light/12 h dark). The Animal Care Com-
mittee of the Faculty of Health Sciences at McMaster University approved all experimental
procedures. The studies were carried out in accordance with the guidelines of the Canadian
Council of Animal Care. The health of the animals was assessed at least twice per day, and any
animal in distress or having lost>15% of their original body weight was euthanized by an over-
dose of sodium pentobarbital.
Onset of macroscopic polyp formation
To determine at what age ApcMin/+ mice began to exhibit macroscopically visible polyps, we
euthanized groups of three ApcMin/+ mice and three wild-type mice at 5, 6, 8, 10, 12 and 14
weeks of age. The entire small intestine and colon was excised from each mouse, opened by a
longitudinal incision, and blindly examined for polyps (see below). From this pilot study, we
determined that polyps first appeared around week 12. All subsequent studies used week 14 as
the endpoint.
Calculation of Polyp Score
The mice were euthanized with isoflurane. The small intestine and colon were excised, opened
longitudinally and the number and size (diameter) of polyps were blindly scored under a dis-
secting microscope, as described previously [30]. A separate count of the polyps for three
regions of the intestine (duodenum, jejunum and ileum) and for the colon was recorded. A
“total polyp score” was calculated for each mouse, which was the sum of the number of polyps
for all areas. Samples of the intestine and colon were snap-frozen and stored at -80 C for subse-
quent Western blot analysis.
Effects of treatment with ATB-346 and naproxen
Most studies involved treatment with a test drug or vehicle beginning when the ApcMin/+ mice
had reached 6 weeks of age (n5 per group). The mice were treated orally once daily for
between 3 and 14 days with vehicle (95:5, 1% CMC:DMSO), naproxen (1 or 10 mg/kg) or equi-
molar doses of ATB-346. In one experiment the effects of daily treatment with the H2S-releas-
ing moiety of ATB-346 (TBZ) were assessed. In all experiments, the presence of intestinal and
colonic polyps was assessed when the mice had reached 14 weeks of age.
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Western blot analysis
Western blot analysis was used to determine expression of two proteins linked to colon cancer,
cMyc and β-catenin [31]. In week 14 of life, samples of colon 2 cm from the cecum were col-
lected from ApcMin/+ mice that had treated during weeks 6 and 7 of life with ATB-346,
naproxen or vehicle, and from vehicle-treated C57Bl/6 mice. The tissue was homogenized in
ceramic bead tubes (1.8 mm tubes) (Mo Bio Laboratory Inc., Carlsbad, CA, USA) using Pre-
cellys 24 homogenizer (Bertin Technologies Corporations, Paris, France) for 3 intervals of 35
seconds at 6500 rpm. In a lysis buffer containing 50 mmol/l Tris (pH 8.0), 0.5% NP-40, 1
mmol/l EDTA, 150 mmol/l NaCl, 10% glycerol, 50 mmol/l sodium fluoride, 10 mmol/l sodium
pyrophosphate, 1 mmol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonyl fluoride, and
a tablet of protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Proteins
were separated on 4–20% gradient polyacrylamide gels (Biorad, Mississauga, ON, Canada).
Blots were incubated with blocking buffer (5% Bovine Serum Albumin Tris-buffered saline and
Tween 0.05%) for 1 hour (Sigma, St. Louis, MO). They were then incubated in primary anti-
body overnight at 4°C. The blots were then washed with Tris-buffered saline containing 0.05%
tween (3 x 10min). The blots were incubated (1 h, room temperature) with secondary anti-rab-
bit IgG antibody conjugated to horseradish peroxidase (1:1000). Enzymes were visualized
using an enhanced chemiluminescence detection kit on a Chemi-doc gel imaging system (Bio-
Rad). The intensity of the bands was determined and analyzed using ImageLab 2.0 software
(Bio-Rad, Canada). The expression of each enzyme was normalized to the expression of β-
actin (1:1000; Cell Signaling Technology, Beverly, MA, USA). Proteins were separated on
4–20% gradient polyacrylamide gels. Rabbit polyclonal cMyc (1:500) and β -catenin (1:500)
were used (Cell Signaling Technology, Beverly, MA, USA). Enzyme expression was visualized
using a secondary anti-rabbit IgG antibody conjugated to horseradish peroxidase (1:1000) and
an enhanced chemiluminescence detection kit on a Chemi-doc gel imaging system (Bio-Rad,
Canada). The intensity of the bands was determined and analyzed using ImageLab 2.0 software
(Bio-Rad, Canada). The expression of each enzyme was normalized to the expression of β-
actin (Cell Signaling Technology, Beverly, MA, USA, 1:1000).
Transcriptomics analysis
Groups (n = 6–8) of 6-week old, male APCMin/+ mice were treated orally with vehicle (95:5, 1%
CMC:DMSO), naproxen (10 mg/kg) or ATB-346 (equimolar dose) once daily for 7 days. A
group of 6-week old, male C57BL/6 (wild-type) mice were treated on the same days with vehi-
cle. Three hours after the final dose of the test drugs or vehicle, the mice were euthanized with
isofluorane and a laparotomy was performed. A sample of colonic tissue (2 cm distal to the
cecum) was collected and immediately snap-frozen. The samples were homogenized using Pre-
cellys 24 homogenizer (Bertin Technologies, Paris, France) and processed using an RNeasy
Mini Kit in accordance with the manufacturer’s instructions (Qiagen, Toronto, Canada).
Total RNA extracted from colonic tissue was subject to standard microarray procedures.
Purity and quality of RNA was assessed using an Agilent Bioanalyzer (Santa Clara, CA, USA).
Samples were converted to labeled cDNA, fragmented and hybridized to Illumina MouseRef-8
v2.0 BeadChip arrays (Illumina, San Diego, CA, USA) by Source Bioscience (Nottingham,
UK). Analysis of datasets was performed in GeneSpring (Agilent). Raw data were log2 trans-
formed and then quantile-normalized. Pathway analysis of significantly modified genes
between groups was performed in g:Profiler (http://biit.cs.ut.ee/gprofiler/). The transcriptomics
data have been uploaded to the Gene Expression Omnibus, National Centre for Biotechnology
Information.
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Statistical analysis
All data are expressed as the mean ± standard error of the mean (SEM). Comparisons among
groups of data were performed by one-way analysis of variance followed by a post hoc test
(Dunnett’s Multiple Comparison Test for parametric data and MannWhitney Test for non-
parametric data). In the case of the transcriptomics data, a one-way analysis of variance with
Student-Neuman-Keuls post-hoc test and Storey’s bootstrapping multiple comparison correc-
tion were employed. With all analyses, an associated probability (p value) of less than 5% was
considered significant.
Materials
ATB-346 (2-(6-methoxy-napthalen-2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester) was
provided by Antibe Therapeutics Inc. (Toronto, ON, Canada). Naproxen sodium and diallyl
disulfide were obtained from Sigma-Aldrich (Oakville, ON, Canada). Isoflurane was obtained
from Abbott Laboratories (Montreal, Canada). TBZ (4-hydroxythiobenzamide) was purchased
from SynChem Inc. (Des Plaines, IL, USA).
Results
Significant numbers of polyps were apparent in the colon and small intestine by 12 weeks of
age in the APCMin/+ mice. Based on this observation, we selected week 14 as the time for evalu-
ation of the number of polyps in our experiments. None of the wild-type mice developed pol-
yps (Fig 1A). In sharp contrast, all of the vehicle-treated APCMin/+ mice had polyps ranging in
diameter from 1 to 4 mm (Fig 1B) and were found throughout the small intestine, but most
predominantly in the terminal ileum (Fig 1C). The vehicle-treated APCMin/+ mice also pre-
sented with several colonic polyps that were generally larger in size than the intestinal polyps,
ranging in diameter from 3 to 6 mm. These polyps were found throughout the colon, including
the cecum.
ATB-346 significantly inhibited polyp formation
APCMin/+ mice treated daily for 14 days (during the 6th and 7th weeks of life) with naproxen at
a dose of 1 mg/kg (4.3 μmol/kg) had similar numbers of polyps as vehicle-treated APCMin/+
mice (Fig 2). In contrast, daily treatment with ATB-346 at an equimolar dose resulted in 51%
reduction (p<0.01) in the total polyp score. With a higher dose of naproxen (10 mg/kg;
43 μmol/kg), a marked reduction (57%; p<0.001) of the total polyp score was observed. How-
ever, treatment with an equimolar dose of ATB-346 reduced the total polyp score by 98%, sig-
nificantly greater than the effect of naproxen. Daily treatment for 14 days with 4-hydroxy-
thiobenzamide (TBZ), the H2S-releasing moiety of ATB-346, did not significantly affect the
total polyp score at either dose.
The magnitude of reduction of polyp formation in APCMin/+ mice treated with ATB-346
increased with the duration of treatment (Fig 3A). A significant reduction of polyp formation
was observed with only 3 days of treatment (~40%; p<0.001), and progressively greater reduc-
tions were seen with 7, 10 and 14 days of treatment, the latter producing almost complete pre-
vention of polyp formation.
As shown in Fig 1, the number of polyps developing in the colon was lower than in the
ileum. However, the ability of ATB-346 to prevent colonic polyp formation was more rapid in
onset (Fig 4B). Colonic polyp formation was completely prevented by daily treatment with
ATB-346 (14.5 mg/kg) for 7 or more days.
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Treatment with naproxen or ATB-346 for two weeks beginning at 12
weeks of age
Daily treatment of ApcMin/+ mice with ATB-346 (14.5 mg/kg) beginning at 12 weeks of age,
and continuing for 14 days, did not significantly alter the number or intestinal polyps (Fig 4).
In contrast, there was a marked reduction in the number of colonic polyps that were evident at
the end of the study (p<0.01 versus vehicle-treated). Treatment with naproxen (10 mg/kg)
Fig 1. Polyp formation in the small intestine and colon of APCMin+ mice at 12 weeks of age. Panel A
shows ileum from a wild-type (C57Bl/6) mouse, while panel B shows ileum from an APCMin+ mouse (with
numerous polyps visible in the latter). Panel C shows the Polyp Score for 12 APCMin+ mice, illustrating the
regional variation through the small intestine and colon. Each line represents the results from one mouse.
The ileum exhibited the greatest polyp score, while the colon exhibited the lowest.
doi:10.1371/journal.pone.0147289.g001
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Fig 2. Dose-related preventative effects of oral treatment with ATB-346 or naproxen on intestinal
polyp formation in APCMin/+ mice.Groups of at least 6 mice each were treated daily with vehicle, naproxen
(1 or 10 mg/kg), or equimolar doses of ATB-346 or of the hydrogen sulfide-releasing moiety of ATB-346 (TBZ;
4-hydroxythiobenzamide). Treatments were started at week 6 of life, and the numbers and areas (in mm2) of
polyps in the small intestine and colon were blindly assessed at week 14 of life (panels A, B and C show
examples; arrows indicate polyps). Panel D shows the ‘total polyp score’ data (the sum of the areas of all
polyps in each mouse). Data are shown as the mean ± SEM. **p<0.01, ***p<0.001 versus the vehicle-
treated group (one-way ANOVA and Dunnett’s test). Ψp<0.05 versus the group treated with naproxen at the
same dose (Student’s t-test).
doi:10.1371/journal.pone.0147289.g002
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Fig 3. Duration-of-treatment-dependent reduction of total polyp score by ATB-346. Panel A: APCMin/+
mice treated with ATB-346 at 14.5 mg/kg (equimolar to 10 mg/kg of naproxen) for up to 14 days, starting at
week 6 of life, had significantly lower total polyp scores as compared to vehicle-treated mice (***p<0.001
compared to the vehicle-treated group). Data are expressed as mean ± SEM (n5 per group). Panel B:
Hydrogen Sulfide for Intestinal Cancer Chemoprevention
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ApcMin/+ mice treated once daily with ATB-346 for up to 14 days had significantly lower colonic polyp scores
compared to vehicle. In the 7-, 10- and 14-day treatment groups, there was a complete absence of polyps
(p<0.05; Mann-Whitney test; n5 per group). The bars on the figure represent the mean ± SEM.
doi:10.1371/journal.pone.0147289.g003
Fig 4. Colon-specific reduction/reversal of polyps. Initiation of treatment with ATB-346 (14.5 mg/kg once
daily for 14 days) at week 12 had no effect on the small intestinal polyp score (assessed at week 14), but
markedly reduced polyp formation in the colon (**p<0.01).
doi:10.1371/journal.pone.0147289.g004
Hydrogen Sulfide for Intestinal Cancer Chemoprevention
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following the same protocol did not produce a significant reduction of polyp numbers in the
intestine or colon.
ATB-346 normalized β–catenin and cMyc expression in APCMin/+ mice
Expression of the well-established markers of APC-associated tumorigenesis, β–catenin and
cMyc, was significantly elevated in samples of colon from APCMin/+ mice as compared to wild
type mice (Fig 5). Treatment with ATB-346 (14.5 mg/kg) for 7 days normalized expression of
both markers to a significantly greater extent than treatment with an equimolar dose (10 mg/
kg) of naproxen.
Differential effects of naproxen versus ATB-346 on the transcriptome in
the colon of APCMin/+ mice
To determine the influence of naproxen and ATB-346 on expression of genes associated with
polyp formation, a transcriptome-wide analysis of colon tissue from APCMin/+ mice, treated
with naproxen (10 mg/kg), ATB-346 (14.5 mg/kg) or vehicle for 7 days (between 6 and 7 weeks
of age) was conducted. As a comparator, tissue from vehicle-treated wild-type (C57Bl/6) mice
was also studied to determine the effect of the APCMin/+ mutation on the transcriptome of the
colonic tissue.
Box and whisker plots of all raw intensity values showed little variation among samples
from all groups analyzed. Principle component analysis showed minimal clustering of global
patterns, which likely reflects relatively modest changes in the transcriptome among the groups
(data not shown).
In the present study we identified 20 genes with1.5-fold increases colonic expression
related to the APCMin/+ mutation (Fig 6). Treatment with ATB-346 resulted in a reduction of
expression of 18 of these genes to the levels observed in wild-type mice. Treatment with
naproxen resulted in a comparable reduction in expression of 7 genes to that achieved with
ATB-346, and the expression of a further 11 genes was partially reduced by naproxen (not
achieving statistical significance in most cases). There were two genes with significantly
reduced expression related to the APCMin/+ mutation (versus wild-type), neither of which was
affected by treatment with ATB-346 or naproxen (Fig 6). One gene (Reg3b) was markedly up-
regulated by naproxen, but not by ATB-346.
Pathway analysis revealed that the affected genes included some implicated in metabolism
of phospholipids (GO:0006644) and lipids (GO:0006629), as well as hydrolase activity
(GO:0016787). Enriched network analysis of pathway interactions showed a hub around
Apoa1, which encodes for apolipoprotein A1. There were no significant associations to recog-
nized cancer-associated networks of the genes altered by ATB-346 or by naproxen. However,
two of the genes with increased expression in APCMin/+ mice, Pnliprp1 and Pnliprp2, are regu-
lated by Runx1 [32], which is known to be an Nrf2-controlled gene [33]. Nrf2 can protect tis-
sues from a variety of carcinogens by increasing the expression of a number of cytoprotective
genes, and Nrf2 can be activated by H2S [33,34].
Discussion
The US National Cancer Institute has predicted that there will be over 130,000 new cases of
colon cancer in the USA in 2015, and almost 50,000 colon cancer-related deaths [1]. Chemo-
prevention strategies for GI cancers have been pursued for decades, particularly focused on the
use of aspirin and other NSAIDs [4,5]. However, the propensity of COX inhibitors to cause
bleeding in the GI tract and elsewhere has been the major limitation to this approach [9,10]. In
the present study, we have demonstrated that a novel type of NSAID derivative, which does
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Fig 5. Treatment with ATB-346 reduced intestinal β-catenin and cMyc levels in APCMin/+ mice.
Expression of both β-catenin (panel A) and cMyc (panel B) were significantly elevated in colonic tissue from
APCMin/+ mice as compared to wild-type mice. Treatment of APCMin/+ mice with ATB-346 (14.5 mg/kg)
significantly reduced β-catenin and cMyc expression to levels comparable to those in wild-type mice, while
naproxen treatment (10 mg/kg) reduced cMyc but not β-catenin. Tissue samples were collected from the
mice at 14 weeks of age, while drug treatment occurred in the 6th and 7th weeks of age. Each bar represents
the mean ± SEM for at least 4 mice (p<0.05 vs. wild-type mice; ψp<0.05 vs. wild type. *p<0.05 vs. naproxen-
treated).
doi:10.1371/journal.pone.0147289.g005
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not produce GI damage at anti-inflammatory doses [25,35], is also substantially more effective
than the parent NSAID (naproxen) in preventing the formation of polyps in a mouse model
that closely mimics heritable intestinal polyposis in humans [3]. The reduced GI-damaging
effects of ATB-346 (and other H2S-releasing NSAIDs) [24–26] is attributable to its ability to
release small amounts of H2S [36], which has been shown to have potent anti-oxidant, cytopro-
tective and anti-inflammatory effects in the GI tract and in other tissues [12,13–23].
In the present study, ATB-346 produced significant beneficial effects in the APCMin+ mouse
model when given for a period as short as 3 days, and was effective in the colon even when
administered after polyps had already formed. ATB-346 was significantly more potent than
naproxen in reducing polyp formation, despite inhibiting COX activity in the GI tract to the
same extent [25,30,36]. These effects of ATB-346 were accompanied by a normalization of tis-
sue expression of two well-characterized cancer markers, β-catenin and cMyc, with
Fig 6. Summary of transcriptomics analysis.Genes altered by >1.5-fold in the colon of APCMin/+ mice as
compared to wild-type mice, and the effects of daily treatment for one week with naproxen or ATB-346. Fold-
change values represent direction of change from the first listed condition to the second. During the 6th week
of age, mice were treated with vehicle, naproxen at a dose of 10 mg/kg, or ATB-346 at an equimolar dose.
Tissue samples were harvested at the start of the 7th week of age. *p<0.05 by one-way ANOVA with Student-
Neuman-Keuls post-hoc test and Storey’s bootstrapping multiple comparison correction. n = 6-8/group.
doi:10.1371/journal.pone.0147289.g006
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significantly greater effects than an equimolar dose of naproxen. Moreover, treatment with
ATB-346 reduced the expression (to wild-type levels) of 18 of the 20 genes that were over-
expressed in APCMin+ mice.
The enhanced effectiveness of ATB-346 in reducing polyp formation in APCMin+ mice is
likely due to the H2S released from this drug. In support of this statement, there are a number
of reports that H2S donors and NSAID-H2S conjugates reduced the incidence and/or severity
of cancer in a range of animal models and cell lines, including cell lines that do not express
COX [27–30,37]. On the other hand, administration of TBZ (the H2S-releasing moiety of
ATB-346) did not significantly affect the polyp score at either dose tested (see Fig 2). However,
this may be a consequence of reduced generation of H2S from the compound when adminis-
tered alone, as compared to that from the ATB-346 conjugate. We have previously observed
that the amount of H2S released from TBZ when it is bound to naproxen (i.e., ATB-346) is
4-fold greater than the release detected from the TBZ molecule alone [38].
The transcriptomic analysis of ~25,000 genes revealed that there were 20 genes that were
up-regulated1.5-fold in the colon of APCMin+ versus wild-type mice, and treatment with
ATB-346 fully reduced expression of 18 (90%) of those genes to normal levels. Naproxen only
fully reduced expression of 7 of the genes, and partially reduced expression of 11 genes. These
findings suggest that the normalization of gene expression in the colon by ATB-346 may have
occurred in part because of effects on COX activity, but other actions of the drug must have
also contributed, since ATB-346 and naproxen inhibit COX to a comparable extent at equimo-
lar doses. Again, the release of H2S from ATB-346 is the most likely explanation for these dif-
ferences. COX-2 is a key oncogene in a number of human cancers. Celecoxib (a selective COX-
2 inhibitor) was being developed as a preventative therapy for colon cancer until cardiovascular
safety concerns arose that limited its use for such applications [39]. In addition, all NSAIDs,
including those with selectivity for COX-2, can cause significant damage and bleeding through-
out the gastrointestinal tract [9,10], and this is a major limitation to use of drugs like aspirin
and naproxen for long-term chemoprevention of cancer.
The gene most profoundly down-regulated by ATB-346 was Ela2a (elastase 2), which
encodes for the proteasome chymotrypsin-like enzymes. Although they have not been directly
associated with gastrointestinal cancers, these enzymes are likely to be involved in tumor inva-
siveness, due to their matrix degradation properties [40]. This hypothesis is supported by the
fact that proteasome inhibitors have shown therapeutic promise in a variety of tumor types
[41]. It is noteworthy that matrix degradation can be modulated by H2S [42]. Other cancer-
associated genes of interest that were profoundly down-regulated by ATB-346 (and less so by
naproxen) included: (i) Reg1, which is up-regulated in human colorectal cancer [43] and is a
predictor of cancer-associated death [44]; (ii) Cpa1 and Cpb1, which are induced in gastroin-
testinal tumors [45] (iii) Amy2, which is up-regulated in a number of cancers including colonic
neoplasms [46] and (iv) Pnliprp1, which has been identified in non-dissected tumors and
micro-dissected invasive tumor cells [47]. The contribution of these ATB-346-sensitive genes
to colon cancer remains the subject of investigation. However, it was striking that many of the
genes down-regulated by ATB-346 were those that were strongly up-regulated in the APCMin/+
colon compared to wild-type, suggesting that ATB-346 can reverse much of the pre-cancerous
gene expression profile in the colon in this model. A full and detailed validation of these genes
may lead to the identification of novel pathways that not only reveal the mechanism underlying
the COX-independent actions of ATB-346, but also novel targets for future drug development.
The transcriptomics analysis identified an unusual and specific effect of treatment with
naproxen. Naproxen-treated APCMin+ mice exhibited a>8-fold increase in expression of the
Reg3b gene as compared to vehicle-treated APCMin+ mice (21-fold greater than expression in
wild-type mice). Reg3b is expressed in mouse intestine [48], and it encodes murine orthologues
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of human pancreatitis-associated proteins. These proteins are involved in the innate immune
response to bacterial colonization of the intestinal tract [49]. The reason that Reg3b gene was
up-regulated specifically in naproxen-treated is likely a consequence of the well-characterized
damaging effects of naproxen in the intestine, and the ensuing bacterial colonization of the
damaged regions [50,51]. Up-regulation of Reg3b has been reported in murine models of colitis
[49]. The lack of a similar up-regulation of Reg3b in ATB-346-treated APCMin+ mice is consis-
tent with the GI-safe profile of this drug [25,36].
ATB-346 is a novel anti-inflammatory drug that combines COX inhibition and release of
H2S. The substantial increase in GI safety of this drug as compared to conventional NSAIDs
should make it an attractive option for various therapeutic applications. We observed a more
profound beneficial effect of ATB-346 in the colon than in the small intestine, but the reasons
for this difference are not yet clear. The results of the present study suggest that ATB-346 may
be a particularly useful compound for chemoprevention, and possibly reversal, of cancers in
the GI tract.
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